News and Events

Government pledges additional Continuous Glucose Monitoring Subsidy for all Australians living with type 1 diabetes

Posted 21 Apr 2022

Dexcom and AMSL Diabetes welcome the recent bi-partisan commitment to providing access to continuous glucose monitoring for all people with Type 1 diabetes in Australia. Expanding the subsidy access to all people with Type 1 diabetes in Australia irrespective of their age and concession card status is an important reform that improves the equity of access to these important... Read more

National Diabetes Services Scheme (NDSS) fully subsidises the most advanced Dexcom Continuous Glucose Monitoring (CGM) technology

Posted 3 Feb 2022

Advanced features not available on any other device Government paves the way for improved access to game-changing technology for eligible Australians living with Type 1 diabetes Sydney, 8 February 2022 – AMSL Diabetes has today announced that the Dexcom G6 Continuous Glucose Monitoring (CGM) system will be available through the Australian Government’s CGM Subsidy... Read more

Dexcom, Inc. acquires AMSL and NZMS

Posted 5 Aug 2021

August 2021 Richard Plowright, Managing Director and Owner of Australasian Medical & Scientific Limited (AMSL) and New Zealand Medical & Scientific (NZMS) has announced his retirement, after over 30 years of providing the Australasian market with access to leading edge healthcare solutions from all over the world. As of the 1st August 2021, Richard has sold all his shares in both... Read more

Tandem Suspension Lifted

Posted 7 Apr 2021

7th April 2021 The Therapeutic Goods Administration (TGA) suspension of the ARTG entry for the Tandem Diabetes Care t:slim X2 insulin pump has officially been lifted. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA and have now successfully addressed their concerns for the t:slim X2 insulin pump. For more information on what these concerns were and how... Read more

Tandem t:slim X2 Insulin Pump with Dexcom G5 Mobile Integration Supply Update

Posted 29 Mar 2021

As of 29th March 2021, AMSL Diabetes has discontinued the sale of the t:slim X2 insulin pump with Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) integration. This announcement does not affect the supply of the t:slim X2 insulin pump with Basal-IQ™ technology and any subsequent versions of the pump. Existing customers will still be supported throughout their warranty period by AMSL... Read more

Introducing the new product distributed by AMSL Medical - Amino-Ther!

Posted 1 Feb 2021

AMSL Medical is delighted to announce that we will be distributing Amino-Ther®, a wonderful new product, within Australia. Amino-Ther is a Food for Special Medical Purposes (FSMP) containing precise quantities of the specific Essential Amino Acids and 3 organic acids (succinic, malic and citric acid) which act as a mitochondrial metabolism modulator, assisting in energy production... Read more

The Australian Government has updated the NDSS CGM Subsidy Initiative

Posted 15 Jan 2021

The Australian Government has updated the NDSS CGM Subsidy Initiative to include the NEW Dexcom G6 Continuous Glucose Monitoring System. As of Monday 18th January 2021, if you are using a Tandem t:slim X2 insulin and are eligible for the NDSS CGM Subsidy Initiative, you can now have access to either Dexcom G5 Mobile CGM or the NEW Dexcom G6 CGM System. The Dexcom G6 is only compatible... Read more

AMSL Scientific Shop

Posted 10 Dec 2020

The AMSL Scientific Division is proud to announce the launch of their new online store, The online store features a range of products that are popular in the industry for reducing time, minimising costs and preventing contamination. For further information on the entire Scientific portfolio, or for bulk orders please contact us at or on... Read more

Tandem Suspension Notice (Last Updated 1 April 2021)

Posted 24 Nov 2020

Latest Update: 1st April 2021 The TGA suspension for the t:slim X2 insulin pump has officially been lifted. For the latest information on this notice, please click here. Recently the Therapeutic Goods Administration (TGA) expressed concern about the Tandem Diabetes Care t:slim X2 insulin pump. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA to address... Read more

AMSL Medical Portfolio expands into Amino Acid Formulas

Posted 24 Sep 2020

AMSL Medical Portfolio expands into Amino Acid Formulas The AMSL Medical Division is delighted to announce their partnership with Professional Dietetics International (PDI). PDI is a privately owned company based in Milan, Italy, who specialise in patented amino acids formulas. PDI produce food for special medical purpose (FSMP), creating precise quantities of specific Essential Amino... Read more

Introducing the Basal-IQ Technology Update for the t:slim X2 Insulin Pump

Posted 10 Aug 2020

Basal-IQ technology is now available in Australia!   The t:slim X2 insulin pump with Basal-IQ technology is compatible with the new Dexcom G6 CGM System^. Basal-IQ technology helps to reduce the frequency and duration of low-glucose events1 by predicting glucose levels 30 minutes ahead and suspending insulin if they are expected to drop below 4.4 mmol/L,... Read more

Romer Labs Seminar: New Developments in Allergen Management and Cleaning

Romer Labs Seminar: New Developments in Allergen Management and Cleaning

Posted 11 May 2020

The prevalence of food allergies has been increasing in recent decades worldwide. It is of upmost importance to not only have correct product labelling, but also to establish appropriate allergen management programmes to ensure no cross-contamination occurs in production facilities. In this webinar, Romer Labs will lead a discussion on new updates in allergen management and... Read more

Important Update: AMSL's Commitment during COVID-19

Posted 24 Mar 2020

Important Message from AMSL General Manager, Ian Slater on COVID-19 The impact of COVID-19 has been unprecedented as it continues to affect people and organisations around the world. The Federal Government, State Governments and Health Authorities continue to provide detailed guidelines on how to mitigate risks and ensure containment. We encourage all of our customers to review these... Read more

AMSL Medical Portfolio Expands in 2020

Posted 20 Mar 2020

The Return of the ACE Stopper!AMSL Medical are pleased to announce that the Medicina ACE Stopper is now available for supply, back by popular demand. Medicina ACE Stoppers are small, implant grade silicone stoppers, that are used to seal stoma sites at various parts of the body. All 12 ACE Stopper sizes along with the Caecostomy Extension Set are available now and... Read more

The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative

Posted 2 Mar 2020

From the 1st of March, 2020, the Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM devices through the National Diabetes Services Scheme (NDSS).... Read more

Dexcom G6 CGM System Update

Posted 2 Mar 2020

We are delighted to announce that the Dexcom G6 Continuous Glucose Monitoring (CGM) System, has been registered in Australia (ARTG 330535).   Dexcom G6 represents the latest addition to the AMSL Diabetes product range, which includes the Dexcom G5 Mobile CGM, Tandem t:slim X2™ insulin pump, V-Go insulin patch pump for type 2 diabetes, Lifescan... Read more

AMSL Medical attends Global Collatamp G Seminar in Paris, France

Posted 18 Feb 2020

On January 27th - 29th 2020, National Sales Supervisor, Amy Antenucci, attended the 1st global Collatamp G seminar in Paris, France. The interactive meeting aimed to extend the knowledge on Collatamp G and share best practice among delegates. Hosted by SERB, the global distributor of Collatamp G, the meeting was attended by representatives from Europe, UK, South Korea, Singapore,... Read more

AMSL Point of Care Recognised at Global Horizon Distributor Meeting with 'Best Percentage Growth in Sales'

Posted 12 Feb 2020

AMSL Point of Care have been awarded ‘Best Percentage Growth in Sales’ and ‘Best Practice Selling Whole Portfolio’ at the Global Horizons Distributor Meeting in Bangkok in October 2019. AMSL Point of Care are the Australian distributors of Nova Biomedical products such as StatStrip® Glucose/Ketone and Lactate meters as well as the StatProfile Prime... Read more

AMSL Diabetes partner with MannKind Corporation

Posted 17 May 2019

Sydney, Australia, May 2019 – AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market. The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution to their diabetes management.... Read more

AMSL Diabetes to distribute MedAngel ONE in Australia

Posted 3 Apr 2019

Sydney, Australia, April 2019 – AMSL Diabetes are delighted to announce that they have agreed to distribute MedAngel products in Australia. MedAngel aims to empower patients with intuitive technology to assist them in monitoring the temperature of their temperature-sensitive medications such as insulin. AMSL Diabetes will be distributing MedAngel ONE, a Bluetooth® temperature... Read more

The Australian Government announces Continuous Glucose Monitoring (CGM) Subsidy Initiative Expansion

Posted 1 Mar 2019

 The Australian Government is extending access to fully subsidised continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS) to now include eligible patients aged over 21 years with type 1 diabetes. Previously, only patients aged 21 years or under were eligible for subsidised CGM.  Both Dexcom G5 Mobile and Dexcom G4 PLATINUM Systems are now... Read more

NDSS Blood Glucose Strips Review Press Release

Posted 15 Nov 2018

Inclusion of OneTouch Verio Blood Glucose Test Strips on the new National Diabetes Services Scheme (NDSS) Product Schedule ­­­­­­­­­­­___________________________________________________________________ Sydney, Australia, November 2018 – The Australian Government recently undertook a review of certain products on the NDSS Product Schedule, with the... Read more

AMSL Diabetes partner with Tandem Diabetes Care, Inc.

Posted 24 Apr 2018

AMSL Diabetes announce new partnership with Tandem Diabetes Care in Australia. AMSL Diabetes are delighted to announce they have partnered with Tandem Diabetes Care®, Inc. to introduce their innovative product range to the Australian market for the very first time. The exclusive partnership is set to benefit Australian type 1 diabetes patients by offering them a new leading edge choice for... Read more

CDR FoodLab, BeerLab and WineLab is now available in Australia!

Posted 24 Jan 2018

Distributed by AMSL Scientific, CDR FoodLab analysis systems provides onsite chemical analyses for food and beverage quality control, with high accuracy and sensitivity. With just one device, CDR FoodLab allows the user to analyse 16 samples or several analytical parameters at the same time, in just a number of minutes. This can be performed entirely in-house, without the need of external... Read more

StatStrip Glucose/Ketone Meters are officially cleared for Critical Care Use in Australia

Posted 4 Jan 2018

AMSL Point of Care is very excited to announce that the StatStrip Glucose/Ketone Meters are officially cleared for use in Critical Care settings (ICU, ED, NICU etc.) and documented within the updated ARTG Certificate. This makes StatStrip the only Point of Care Glucose meter currently on the market that is cleared for use in Critically ill patients in Australia. For more information on... Read more

Dexcom Continuous Glucose Monitoring (CGM) now available on the Government Subsidy Initiative

Posted 8 May 2017

The Australian Government is now providing access to fully subsidised continuous glucose monitoring (CGM) products through the National Diabetes Services Scheme (NDSS). Subsidised access to Dexcom G5 Mobile and Dexcom G4 PLATINUM CGM sensors and transmitters is available through the NDSS to children and young people aged under 21 years, living with type 1 diabetes, who meet specific criteria.... Read more